文献速递浆细胞疾病

噻唑烷-2,4-二酮类Pim抑制剂对多发性骨髓瘤的独特抗骨髓瘤活性

Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
PubMed 文献 · Br J Haematol · 2018-01-01

研究验证不同PIM抑制剂对多发性骨髓瘤(MM)细胞的疗效。噻唑烷-2,4-二酮类化合物SMI-16a和SMI-4a在酸性条件下优先降低PIM2蛋白水平并损害MM细胞存活,而AZD1208、CX-6258和PIM447无此优先性;SMI-16a抑制乳腺癌耐药蛋白外排功能、缩小侧群并降低体外集落形成和体内致瘤活性;SMI-16a减轻卡非佐米引起的PIM2蛋白升高并协同增强抗MM效果。

要点

  • SMI-16a和SMI-4a在酸性条件下优先降低MM细胞PIM2蛋白并损害存活。
  • SMI-16a抑制乳腺癌耐药蛋白外排、缩小侧群并降低集落形成和体内致瘤性。
  • SMI-16a减轻卡非佐米引起的PIM2蛋白升高并协同增强抗MM效果。

核心结论

  • 噻唑烷-2,4-二酮类化合物SMI-16a和SMI-4a独特降低MM细胞PIM2蛋白,除直接激酶抑制外可能贡献其深度疗效,与蛋白酶体抑制剂联合被设想。

研究设计与样本

  • 研究验证不同PIM抑制剂对MM细胞的疗效,使用SMI-16a、SMI-4a、AZD1208、CX-6258和PIM447,检测PIM2蛋白水平、细胞存活、药物外排、侧群、体外集落形成和体内致瘤活性。

主要发现

  • SMI-16a和SMI-4a在酸性条件下优先降低PIM2蛋白水平并损害MM细胞存活,而AZD1208、CX-6258和PIM447无此优先性。
  • SMI-16a抑制乳腺癌耐药蛋白外排功能、缩小侧群并降低MM细胞体外集落形成能力和体内致瘤活性。
  • 硼替佐米和卡非佐米增加MM细胞PIM2蛋白水平而不影响其mRNA水平;SMI-16a减轻该PIM2蛋白升高并与卡非佐米协同增强抗MM效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of different types of PIM inhibitors against MM cells for their possible clinical application. Intriguingly, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a reduced PIM2 protein levels and impaired MM cell survival preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. SMI-16a also suppressed the drug efflux function of breast cancer resistance protein, minimized the sizes of side populations and reduced in vitro colony-forming capacity and in vivo tumourigenic activity in MM cells, suggesting impairment of their clonogenic capacity. PIM2 is known to be subject to ubiquitination-independent proteasomal degradation. Consistent with this, the proteasome inhibitors bortezomib and carfilzomib increased PIM2 protein levels in MM cells without affecting its mRNA levels. However, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects in combination with carfilzomib. Collectively, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein in MM cells, which may contribute to their profound efficacy in addition to their immediate kinase inhibition. Their combination with proteasome inhibitors is envisioned.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Fujii S, Nakamura S, Oda A, et al. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity. Br J Haematol. 2018. PMID: 29327347. doi:10.1111/bjh.15033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。